Tuesday, May 5, 2026

Dicello Levitt and Wagstaff Drive Surge in CPAP and Talc Dockets as GLP-1 Filings Mount

Federal dockets saw a concentrated burst of mass tort activity yesterday, with over 140 new multidistrict litigation and product liability filings driving the daily volume. The bulk of the momentum centered on established medical device and pharmaceutical dockets, led by a massive single-firm push in the Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Liability Litigation (MDL 3014) with 36 new filings driven entirely by Dicello Levitt LLP. Meanwhile, the Johnson & Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability Litigation (MDL 2738) registered 23 new complaints, spearheaded by Wagstaff Law Firm and supported by Weitz & Luxenberg PC. The Bard Implanted Port Catheter Products Liability Litigation (MDL 3081) showcased diverse plaintiff-side participation, drawing 18 new filings from seven different firms including Price Armstrong LLC and Lanier Law Firm. Rounding out the top volume, the Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation (MDL 3140) added 12 cases across eight firms, claiming the contraceptive injection significantly increases the risk of developing intracranial meningiomas.

Parker Waichman Files South Carolina Lawsuit Alleging Ozempic Causes Irreversible Vision Loss

On May 4, 2026, Parker Waichman LLP announced the filing of a lawsuit in the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (MDL 3163) on behalf of a South Carolina resident who developed permanent vision loss after using Ozempic. The complaint, Huth v. Novo Nordisk Inc., alleges the manufacturer failed to warn patients and medical professionals about the risk of NAION, a condition causing sudden blindness. The litigation relies on recent scientific studies from Harvard's Mass Eye and Ear, which concluded that diabetic users of semaglutide face a fourfold increased risk of developing the condition. This action adds momentum to the newly formed MDL before Judge Karen S. Marston, where plaintiffs' leadership is moving aggressively to establish general causation connecting the blockbuster weight-loss drug to severe optic nerve damage.

Village of Maine Residents Confront 3M Over Severe PFAS Well Contamination

On May 3, 2026, residents of the Village of Maine, Wisconsin, voiced escalating concerns over severe per- and polyfluoroalkyl substances (PFAS) contamination in their private drinking water wells during a community town hall. The crisis centers on a class-action lawsuit filed against 3M, alleging the company's nearby Greystone Facility and Quarry disposed of PFAS-laden materials that leached into the local groundwater supply. Testing by the Wisconsin Department of Natural Resources revealed alarmingly high concentrations of the forever chemicals, with PFOA and PFOS levels reaching 210 parts per trillion and 310 parts per trillion respectively—far exceeding state and federal safety thresholds. As families face the financial burden of installing expensive filtration systems and relying on bottled water, the litigation seeks compensation for remediation costs, diminished property values, and comprehensive medical monitoring.